Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.62 |
| ▸ | KDR | P35968 | 4/20 | 0.62 |
| ▸ | PLK4 | O00444 | 3/20 | 0.62 |
| ▸ | RET | P07949 | 3/20 | 0.62 |
| ▸ | FLT3 | P36888 | 3/20 | 0.62 |
| ▸ | PLK1 | P53350 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 2/20 | 0.62 |
| ▸ | SNCA | P37840 | 2/20 | 0.62 |
| ▸ | CTRC | Q99895 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478494 | 1.00 | PDGFRB (0.62) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5476173 | 0.84 | RAF1 (0.71) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5476171 | 0.84 | RAF1 (0.71) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5481961 | 0.83 | PDGFRB (0.72) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5481962 | 0.83 | PDGFRB (0.72) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5469764 | 0.82 | PLK4 (0.70) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5469759 | 0.82 | PLK4 (0.70) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL21179876 | 0.81 | PDGFRB (0.51) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5474945 | 0.81 | MAPT (0.68) | PDGFRBKDRPLK4RETFLT3 | |
| SCHEMBL5469417 | 0.81 | KDR (0.73) | PDGFRBKDRPLK4RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | PDGFRB 4421/4885KDR 4334/4885PLK4 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.